Business
Genprex Appoints Suzanne Thornton-Jones as Senior Vice President, Regulatory Affairs
Strengthens management team with seasoned regulatory expert to support pipeline of gene therapies for the treatment of cancer and diabetes, including two
About this update from Genprex, Inc.
[{"type":"text","content":"Strengthens management team with seasoned regulatory expert to support pipeline of gene therapies for the treatment of cancer and diabetes, including two clinical trials in Non-Small Cell Lung Cancer and one in Small Cell Lung Cancer \nAUSTIN, Texas, Aug. 22, 2023 /PRNewswire/ -- Genprex, Inc. (\"Genprex\" or the \"Company\") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the appointment of Suzanne Thornton-Jones, Ph.D. as Senior Vice President, Regulatory Affairs. Dr. Thornton-Jones will leverage her regulatory expertise to guide and oversee the Company's regulatory submissions and strategy for Genprex's pipeline of gene therapy drug candidates.\n\n \n \n \n \n \n \n\n \n\"We are delighted to welcome Dr. Thornton-Jones to the Genprex team as her strategic regulatory and drug development expertise, including with novel gene therapy products, will be invaluable as we advance our innovative gene therapies to treat cancer and diabetes,\" said Rodney Varner, Chairman, President and Chief Executive Officer at Genprex. \"We look forward to benefitting from Dr. Thornton-Jones' deep domain experience at this important point in Genprex's growth, particularly as we advance and expand our clinical development programs in oncology with our REQORSA® Immunogene Therapy drug candidate, and progress the development of our diabetes gene therapy program toward first-in-human studies. We look forward to Dr. Thornton-Jones' guidance as we drive these important clinical programs forward.\"\nDr. Thornton-Jones has more than 25 years of experience in drug development and extensive experience in regulatory strategy and regulatory affairs. Before joining Genprex, she was Vice President, Head of Regulatory Affairs and Project Team Lead at Tavanta Therapeutics, where Dr. Thornton-Jones established and directed robust regulatory strategies in support of early and late phase specialty products in the Tavanta portfolio. She lead the development and regulatory strategy for submission of regulatory documents to global regulatory agencies. Prior to that, Dr. Thornton-Jones was Vice President, Regulatory Affairs and Project Team Lead at Affinia Therapeutics, where she established and directed regulatory strategies in support of novel neurodevelopment and n...